SkinBioTherapeutics (LON:SBTX) Posts Earnings Results

SkinBioTherapeutics (LON:SBTX) announced its quarterly earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

SkinBioTherapeutics Price Performance

Shares of LON SBTX traded down GBX 0.10 ($0.00) during midday trading on Friday, hitting GBX 24 ($0.31). 575,179 shares of the company’s stock were exchanged, compared to its average volume of 817,032. The business’s fifty day moving average price is GBX 20.16 and its two-hundred day moving average price is GBX 16.70. The company has a current ratio of 0.93, a quick ratio of 10.01 and a debt-to-equity ratio of 27.57. The company has a market cap of £54.82 million, a price-to-earnings ratio of -14.76 and a beta of 2.01. SkinBioTherapeutics has a 12-month low of GBX 8.32 ($0.11) and a 12-month high of GBX 26.45 ($0.34).

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.